These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 29036018)

  • 1. Precision medicine in asthma: linking phenotypes to targeted treatments.
    Chung KF
    Curr Opin Pulm Med; 2018 Jan; 24(1):4-10. PubMed ID: 29036018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypes/endotypes-driven treatment in asthma.
    Braido F; Tiotiu A; Kowal K; Mihaicuta S; Novakova P; Oguzulgen IK
    Curr Opin Allergy Clin Immunol; 2018 Jun; 18(3):184-189. PubMed ID: 29601354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies.
    Chung KF
    J Intern Med; 2016 Feb; 279(2):192-204. PubMed ID: 26076339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics, phenotypes, mechanisms and management of severe asthma.
    Chung KF; Dixey P; Abubakar-Waziri H; Bhavsar P; Patel PH; Guo S; Ji Y
    Chin Med J (Engl); 2022 May; 135(10):1141-1155. PubMed ID: 35633594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applying personalized medicine to adult severe asthma.
    Tiotiu A
    Allergy Asthma Proc; 2021 Jan; 42(1):e8-e16. PubMed ID: 33404396
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular Targets for Biological Therapies of Severe Asthma.
    Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
    Front Immunol; 2020; 11():603312. PubMed ID: 33329598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalised medicine in asthma: time for action: Number 1 in the Series "Personalised medicine in respiratory diseases" Edited by Renaud Louis and Nicolas Roche.
    Chung KF
    Eur Respir Rev; 2017 Sep; 26(145):. PubMed ID: 28954768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe asthma: what is new in the new millennium.
    Ntontsi P; Samitas K; Zervas E; Gaga M
    Curr Opin Allergy Clin Immunol; 2020 Apr; 20(2):202-207. PubMed ID: 32004177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choice of biologics in asthma endotypes.
    Wangberg H; Woessner K
    Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):79-85. PubMed ID: 33306486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controversies and opportunities in severe asthma.
    Humbert M; Busse W; Hanania NA
    Curr Opin Pulm Med; 2018 Jan; 24(1):83-93. PubMed ID: 29059087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma?
    De Ferrari L; Chiappori A; Bagnasco D; Riccio AM; Passalacqua G; Canonica GW
    Expert Rev Respir Med; 2016; 10(1):29-38. PubMed ID: 26566089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs.
    Parulekar AD; Kao CC; Diamant Z; Hanania NA
    Curr Opin Pulm Med; 2018 Jan; 24(1):50-55. PubMed ID: 29036019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asthma: personalized and precision medicine.
    Canonica GW; Ferrando M; Baiardini I; Puggioni F; Racca F; Passalacqua G; Heffler E
    Curr Opin Allergy Clin Immunol; 2018 Feb; 18(1):51-58. PubMed ID: 29189350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.
    Albers FC; Müllerová H; Gunsoy NB; Shin JY; Nelsen LM; Bradford ES; Cockle SM; Suruki RY
    J Asthma; 2018 Feb; 55(2):152-160. PubMed ID: 28622052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
    Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
    Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reslizumab in the treatment of severe eosinophilic asthma: an update.
    Walsh GM
    Immunotherapy; 2018 Jun; 10(8):695-698. PubMed ID: 29554826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precision medicine in asthma: the role of bronchial thermoplasty.
    Oberle AJ; Mathur P
    Curr Opin Pulm Med; 2017 May; 23(3):254-260. PubMed ID: 28319473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-IgE therapy with omalizumab for severe asthma: current concepts and potential developments.
    Pelaia G; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Maselli R
    Curr Drug Targets; 2015; 16(2):171-8. PubMed ID: 25523898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moving towards precision care for childhood asthma.
    Mokhallati N; Guilbert TW
    Curr Opin Pediatr; 2016 Jun; 28(3):331-8. PubMed ID: 27093356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.